3D chromatin remodeling potentiates transcriptional programs driving cell invasion
The contribution of deregulated chromatin architecture, including topologically associated domains (TADs), to cancer progression remains ambiguous. CCCTC-binding factor (CTCF) is a central regulator of higher-order chromatin structure that undergoes copy number loss in over half of all breast cancer...
Saved in:
Published in: | Proceedings of the National Academy of Sciences - PNAS Vol. 119; no. 36; pp. 1 - e2203452119 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Washington
National Academy of Sciences
06-09-2022
|
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The contribution of deregulated chromatin architecture, including topologically associated domains (TADs), to cancer progression remains ambiguous. CCCTC-binding factor (CTCF) is a central regulator of higher-order chromatin structure that undergoes copy number loss in over half of all breast cancers, but the impact of this defect on epigenetic programming and chromatin architecture remains unclear. We find that under physiological conditions, CTCF organizes subTADs to limit the expression of oncogenic pathways, including phosphatidylinositol 3-kinase (PI3K) and cell adhesion networks. Loss of a single CTCF allele potentiates cell invasion through compromised chromatin insulation and a reorganization of chromatin architecture and histone programming that facilitates de novo promoter-enhancer contacts. However, this change in the higher-order chromatin landscape leads to a vulnerability to inhibitors of mTOR. These data support a model whereby subTAD reorganization drives both modification of histones at de novo enhancer-promoter contacts and transcriptional up-regulation of oncogenic transcriptional networks. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Author contributions: B.L., M.J., and M.W. designed research; B.L., M.J., T.Z., C.K.W., and E.C.C. performed research; B.L., M.J., S.H., A.A.-M, C.C., M. Buchanan, R.C., L.M., G.D., C.K., M.P., and M. Basik contributed new reagents/analytic tools; B.L., M.J., T.Z., N.W., and M.W. analyzed data; and B.L. and M.W. wrote the paper. Edited by Myles Brown, Dana-Farber Cancer Institute, Boston, MA; received March 11, 2022; accepted July 25, 2022 |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.2203452119 |